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ABSTRACT
Approximately 15% of non-small cell lung cancer
cases are associated with a mutation in the epi-
dermal growth factor receptor (EGFR) gene, which
plays a critical role in tumor progression. With the
goal of treating mutated EGFR-mediated lung cancer,
we demonstrate the use of clustered regularly inter-
spaced short palindromic repeats (CRISPR)/CRISPR
associated protein 9 (Cas9) system to discrimi-
nate between the oncogenic mutant and wild-type
EGFR alleles and eliminate the carcinogenic mu-
tant EGFR allele with high accuracy. We targeted
an EGFR oncogene harboring a single-nucleotide
missense mutation (CTG > CGG) that generates
a protospacer-adjacent motif sequence recognized
by the CRISPR/Cas9 derived from Streptococ-
cus pyogenes. Co-delivery of Cas9 and an EGFR
mutation-specific single-guide RNA via adenovirus
resulted in precise disruption at the oncogenic mu-
tation site with high specificity. Furthermore, this
CRISPR/Cas9-mediated mutant allele disruption led
to significantly enhanced cancer cell killing and re-
duced tumor size in a xenograft mouse model of hu-
man lung cancer. Taken together, these results in-
dicate that targeting an oncogenic mutation using
CRISPR/Cas9 offers a powerful surgical strategy to
disrupt oncogenic mutations to treat cancers; simi-
lar strategies could be used to treat other mutation-
associated diseases.
INTRODUCTION
Lung cancer is one of the most commonly diagnosed ma-
lignant types of cancer. It also accounts for 42% of overall
cancer mortality (1) (https://seer.cancer.gov/statfacts/html/
lungb.html). Despite extensive research, the prognosis of
lung cancer treated with conventional chemical and radi-
ological therapies is poor. Overall, the 5-year survival rate
for patients with metastatic lung cancer is<15% (2). To this
end, improvement in this area requires the development of
highly specific targeted therapeutics.
Several oncogenic mutations that cause lung cancer have
been identified; thus, targeted cancer treatment has be-
come a reality. Aberrant epidermal growth factor receptor
(EGFR) expression has been recognized as a key driver of
cellular proliferation, differentiation, migration and angio-
genesis, ultimately contributing to lung cancer oncogene-
sis (3–9). Approximately 15% of non-small cell lung cancer
(NSCLC) cases, which account for 85% of lung cancers, are
associated with mutations in the EGFR gene. These muta-
tions play critical roles in tumor progression. About 90%
of EGFR activation mutations involve either deletions in
exon 19 or a missense mutation in exon 21 that substitutes
an arginine for a leucine (L858R) in the tyrosine kinase do-
main (10). This classical activating L858Rmutation in exon
21 accounts for ∼40% of all EGFR mutations (11). Target-
ing mutant EGFR has been key in advancing lung cancer
research treatment and improving patient outcomes.
EGFR inhibitors such as gefitinib and erlotinib have been
developed to inhibit the tyrosine kinase activity of mutated
EGFR and are currently the first-line therapies for treating
lung cancer (12,13). However, this targeted therapy often
fails because of secondary genetic mutations that arise after
repeated drug exposure and confer resistance to the targeted
drug. Indeed, most lung cancers in EGFR targeted drug
treatment groups have been reported to acquire resistance
within 2 years, thus requiring second- and third-generation
drugs (14). To transcend the current limitations of targeted
cancer treatments, an alternative strategy would be needed
*To whom correspondence should be addressed. Tel: +82 2 880 9327; Email: jskim01@snu.ac.kr
Correspondence may also be addressed to Chae-Ok Yun. Tel: +82 2 2220 0491; Email: chaeok@hanyang.ac.kr
†These authors contributed equally to the paper as first authors.
C© The Author(s) 2017. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/), which
permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
7898 Nucleic Acids Research, 2017, Vol. 45, No. 13
to eliminate cancer-causing mutations at the DNA level us-
ing targeted nucleases.
Several types of nucleases have been developed for
targeted gene editing. These include RNA-guided pro-
grammable nucleases, which have been repurposed from the
clustered regularly interspaced short palindromic repeats
(CRISPR)/CRISPR associated protein 9 (Cas9) adaptive
immune system in eubacteria and archaea that protects
against invading genetic elements (15–21). For gene edit-
ing, Cas9, derived from Streptococcus pyogenes (SpCas9),
is complexed with target-derived CRISPR RNA (crRNA)
and trans-activating crRNA (tracrRNA) or with a single-
guide RNA (sgRNA) composed of essential portions of
crRNA and tracrRNA that are physically linked for ease
of use. SpCas9 recognizes the 5′-NGG-3′ protospacer-
adjacent motif (PAM) at a target site, whereas its associated
sgRNA or crRNA, which contains 19 or 20 nucleotides (nt)
of complementary target sequence, hybridizes with the tar-
get DNA sequence upstream of the PAMviaWatson–Crick
base pairing. As a result, Cas9 induces a DNA double-
strand break (DSB) 3 nt upstream of the PAM. Repair of
the DSB by error-prone non-homologous end-joining or
microhomology-mediated end joining gives rise to muta-
tions at the cleavage site (22).
Several studies have explored the use of CRISPR/Cas9
for the direct disruption of abnormally activated onco-
genes or the restoration of inactivated tumor suppressor
genes (23–31). To express Cas9 or sgRNA specifically in
cancer cells, various strategies have been reported, such as
the use of cancer-specific promoters, drug-induced sgRNA
vector systems, AND gate genetic circuits regulated by
a cancer-specific promoter and aptamer-liposome systems
(24,29,30). However, without a system that selectively dis-
rupts mutated oncogenes, but not the corresponding wild-
type proto-oncogenes, the value of these approaches will
be limited. The indiscriminate destruction of both alleles
can cause serious side effects because the proto-oncogenes
themselves havemany biologically important roles. To over-
come this limitation, an allele-specific gene editing ap-
proach has been reported to target a mutant allele (32–37).
Yet there is no report in cancer treatment, demonstrating
that allele specific oncogene disruption in vivo leads to tu-
mor growth inhibition.
To address the issues of allelic heterogeneity in cancer
treatment with respect to gene editing, here we demonstrate
a more precise approach to selectively target the mutant
allele. In this study, we targeted a single nucleotide mis-
sense mutation (CTG > CGG) in EGFR, which results
in one of the major EGFR activation mutations (L858R)
in NSCLC. We hypothesized that the mutant EGFR al-
lele could be selectively destroyed by exploiting the fact
that this missense mutation generates a PAM (5′-NGG-
3′) in the genome. We found that delivery of an oncogenic
mutant-specific CRISPR/Cas9 via adenovirus (Ad) results
in the cleavage and disruption of the mutant EGFR allele
with high accuracy, leading to a significant reduction of tu-
mor growth in a mouse lung cancer xenograft model. To
best of our knowledge, our study is first to demonstrate
that CRISPR/Cas9-mediated knockout of L858R muta-
tion in EGFR-overexpressing lung cancers can lead to tu-
mor growth inhibition. This approach has potential for tar-
geting cancers in which EGFR is often mutated or drug
resistant and potential advantages for personalized cancer
treatment relative to conventional therapeutics.
MATERIALS AND METHODS
Cell lines and cell culture
All cell lines were cultured in Dulbecco’s modified Eagle’s
medium (DMEM; Gibco BRL, Grand Island, NY, USA)
supplemented with 10% fetal bovine serum (Gibco BRL),
L-glutamine (2 mM), penicillin (100 IU/ml), and strepto-
mycin (50 g/ml). HEK293 (human embryonic kidney cell
line expressing theAdE1 region) and non-small lung cancer
cell lines (H1975, A549) were purchased from the American
Type Culture Collection (ATCC, Manassas, VA, USA).
Plasmid construction
To generate an Ad construct that expresses sgRNA tar-
geting mutated EGFR (sgEGFR) in the E3 region of E1-
deleted Ad, the U6 promoter and a GX19 sgRNA (5′-
CAAGATCACAGATTTTGGG-3′) that hybridizes with
EGFR exon 21 were synthesized and subcloned into a
pSP72-E3, Ad E3 shuttle vector (38), yielding a pSP72-
E3/sgEGFR shuttle vector. pSP72-E3/sgEGFR was lin-
earized withXmnI and co-transformed into Escherichia coli
BJ5183 along with SpeI-digested dE1-RGD, used as an
empty vector control (39) for homologous recombination,
generating a dE1-RGD/SgEGFR (Ad/sgEGFR) vector.
Adenovirus production
All viruses were propagated in HEK293 cells, and the pu-
rification, titration, and quality analysis of all Ads were
performed as previously described (40,41). Viral particle
(VP) numbers were calculated from measurements of op-
tical density at 260 nm (OD260), where 1 absorbency unit
is equivalent to 1012 VPs per milliliter. Infectious titers
(plaque forming unit per milliliter) were determined by a
limiting dilution assay on HEK293 cells. After viral gener-
ation, polymerase chain reaction (PCR) amplification and
DNA sequencing were performed to verify viral genome
structures. A Cas9-expressing Ad vector was purchased
(Ad/Cas9; Vector Biolabs, Malvern, PA, USA).
Transfection and genomic DNA extraction
SpCas9 plasmid (500 ng) and sgRNA plasmid (1500 ng)
were transfected into cells (1× 105) with lipofectamine 2000
(Invitrogen). After 48 h of transfection, genomic DNA was
isolated using a DNeasy Blood & Tissue kit (Qiagen). For
DNA extraction from tumors, a tumor section was cut into
eight–nine pieces and homogenized using tungsten carbide
beads (3 mm; Qiagen) and a TissueLyser II (Qiagen). Then,
genomicDNAwas isolated using aDNeasy Blood&Tissue
kit (Qiagen).
RNA extraction and qPCR
Total RNA was isolated from H1975 cells using TRI-
zol (Sigma) according to the manufacturer’s protocol.
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One microgram of RNA was then reverse transcribed
using a High-Capacity cDNA reverse transcription
kit (Applied Biosystems). Quantitative PCR was per-
formed using Fast Sybr Green Master mix (Applied
Biosystems) with the following primers: human EGFR,
5′-GTGACCGTTTGGGAGTTGATGA-3′ (forward),
5′-GGCTGAGGGAGGCGTTCTC-3′ (reverse).
Mutation analysis
On-target loci were amplified for targeted deep sequenc-
ing. Deep sequencing libraries were generated by PCR.
TruSeq HT Dual Index primers were used to label each
sample. Pooled libraries were subjected to paired-end se-
quencing (LAS, Inc.). Wild-type and mutated sequences
were discriminated based on the presence of the sin-
gle nucleotide missense mutation in the EGFR allele. In-
dels located 3-bp upstream of the PAM were consid-
ered to be the mutations induced by SpCas9. The in-
del frequency was calculated as described (42). PCR was
performed with the following primers; human EGFR,
5′-CGGATGCAGAGCTTCTTCCCATG-3′ (forward), 5′-
AAGGCAGCCT GGTCCCTGGT-3′ (Reverse).
MTT assays
To evaluate the cytopathic effect of CRISPR/Cas9, 2-5 ×
104 cells were plated onto a 24-well plate at about 70%
confluence and then transduced with a combination of
Ad/sgEGFR and empty Ad vector (Ad/sgEGFR), a com-
bination of Ad/Cas9 and empty Ad vector (Ad/Cas9) or a
combination of Ad/sgEGFR and Ad/Cas9 (Ad/sgEGFR
+ Ad/Cas9) at a multiplicity of infection (MOI) of 10-
50. The killing effect of these treatments was moni-
tored daily under a microscope. At 48 h post-treatment,
a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay was carried out as previously described
(43). In brief, 200 l ofMTT (Sigma) in phosphate buffered
saline (PBS; 2 mg/ml) was added to each well. After 4 h in-
cubation at 37◦C, the supernatant was discarded and the
precipitate was dissolved in 1 mL of dimethyl sulfoxide.
Plates were then read on a microplate reader at 540 nm.
Generation, treatment and analysis of tumor xenografted
mice
Tumors were implanted in the abdomens of 5- to 6-week
old male nude mice by subcutaneous injection of H1975
or A549 cells (1 × 107 cells in 100 l of Hank’s balanced
salt solution (HBSS; Gibco BRL). When tumor volumes
reached a range of 70–100 mm3 within 1–2 weeks of tu-
mor cell injection, animals were randomly assigned to one
of three groups to receive PBS, Ad/Cas9 + empty Ad vector
or Ad/sgEGFR+Ad/Cas9 (seven or eight mice per group)
when they were 6–8 weeks old. The first day of treatment
was designated as day 1. Ad or PBS was administered in-
tratumorally (a total of 5 × 1010 VPs in 30 L of PBS) on
days 1, 3 and 5. Tumor growth inhibition was assessed every
other day by measuring the length (L) and width (w) of the
tumor and determining the tumor volume, with following
formula: volume= 0.523L(w)2. The percentage of surviving
mice was determined by monitoring tumor growth-related
events (tumor size > 800 mm3) over a period of inspection.
Histology and immunohistochemistry
Representative sections were stained with Hematoxylin and
eosin (H & E) and then examined by light microscopy (Carl
Zeiss Inc.). For immunohistochemistry, slides were deparaf-
finized in xylene and then processed as described earlier
(43–46). H1975 tumor tissue sections were incubated at 4◦C
overnight with mouse anti-proliferating cell nuclear antigen
(PCNA: DAKO, Glostrup, Denmark) or goat anti-EGFR
primary antibody (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), rinsed and then incubated for 30 min with a
biotinylated anti-mouse (Cell Signaling Technology, Dan-
vers, MA, USA) or anti-goat secondary antibody (DAKO),
respectively. Sections were then rinsed in buffer and incu-
bated with streptavidin-peroxidase. All slides were coun-
terstained with Meyer’s hematoxylin (Sigma). The results
fromPCNAorEGFR stainingwere semi-quantitatively an-
alyzed by MetaMorph® image analysis software (Univer-
sal Image Corp., Buckinghamshire, UK).
Statistical analysis
No statistical methods were used to predetermine sample
sizes for in vitro or in vivo experiments. All group results
are expressed as mean ± SEM if not otherwise indicated.
Comparisons between groups were made using the one-way
ANOVA with Tukey’s post-hoc tests for multiple groups.
Statistical significance as compared to untreated controls is
denoted with * (P< 0.05), ** (P< 0.01), *** (P< 0.001) in
the figures and figure legends. Statistical analysis was per-
formed in Graph Pad PRISM 5.
Data availability
The deep sequencing data from this study have been submit-
ted to the NCBI Sequence Read Archive (http://www.ncbi.
nlm.nih.gov/sra) under accession number SRX2866619.We
have included the read depth information of the deep se-
quencing data in the Supplementary Tables S3–5.
RESULTS
Precise editing of an oncogenic mutant allele via
CRISPR/Cas9
First, we designed a CRISPR/Cas9 nuclease to discrimi-
nate between the oncogenic mutant and wild-type EGFR
alleles (Figure 1A). The EGFR mutant gene harbors a sin-
gle nucleotide missense mutation (CTG > CGG) in EGFR
exon 21, generating a PAM sequence recognized by SpCas9.
Here, we generated a GX19 sgRNA that hybridizes with the
EGFR mutant allele (sgEGFR). This sgRNA includes an
extra guanine (G) at the 5′-end for transcription under the
control of the U6 promoter; the remaining 19 nucleotides
(X19) hybridize with a 19 nt target DNA sequence upstream
of the newly generated PAM (5′-CGG-3′) sequence in the
oncogene allele.
Then, we examined the activity of the mutant allele-
specific Cas9 nuclease in H1975 cells derived from a patient
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Figure 1. Oncogenic mutant-specific Cas9. (A) A PAM sequence (red) is generated by a single nucleotide missense mutation in the EGFR gene. The
corresponding wild-type sequence is shown in green. The sgRNA target sequence is shown in blue. (B) Diagram of selective cancer cell killing by cleavage
of the oncogenic mutant allele 3-bp upstream of the PAM. (C)Mutation frequencies at theEGFR target site in H1975 cells or A549 cells co-transfected with
Ad/sgEGFR and Ad/Cas9 48 h post-transfection. Mismatched nucleotides are shown in yellow and PAM sequences in red. The sgRNA target sequence
is shown in blue. The column on the right indicates the number of inserted or deleted bases. Bars represent the mean ± S.E.M (n = 3). **P < 0.01, ns: not
significant.
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with NSCLC harboring the EGFR mutant allele (Figure
1B). We found that the H1975 cells contained the mutant
and wild-type alleles at a ratio of 3:1. To confirm oncogenic
mutant-specificDNAcleavage byCas9, we transfected plas-
mids encoding Cas9 and sgEGFR into H1975 cells. A549
lung adenocarcinoma cells, which do not contain the mu-
tant allele, were utilized as a negative control (Figure 1C).
Cas9-induced small insertions/deletions (indels) were de-
tected in the EGFR mutant allele in H1975 cells with a fre-
quency of 3.6% (±0.1%) 2 days post-transfection, whereas
nomutations were detectably induced in the wild-type allele
in either H1975 or A549 cells.
Enhanced cancer cell killing mediated by oncogenic mutant-
specific genome editing
For efficient delivery of CRISPR/Cas9 to cancer cells,
we utilized a replication-incompetent Ad vector. First, we
constructed Cas9-expressing Ad (Ad/Cas9) and sgEGFR-
expressing Ad (Ad/sgEGFR) (Figure 2A). Then, H1975
and A549 cells were transduced with a combination of
Ad/sgEGFR and Ad/Cas9 at MOIs of 10, 20 and 50 (Fig-
ure 2B). Indels accumulated at the target site in a time- and
dose-dependent manner with a frequency of 11% (±4%),
20% (±0.7%) and 56% (±0.7%) 1, 2 and 5 days post
treatment, respectively, at an MOI of 10. At 5 days post-
infection, indels were detected with a frequency of 56%
(±0.7%), 73% (±0.6%) and 79% (±1.2%) in H1975 cells
at MOIs of 10, 20 and 50, respectively, resulting in robust
knock-down of the EGFR mRNA level (Figure 2C). In-
dels were minimally detected at the wild-type EGFR allele
in H1975 cells, with a frequency of 2.8% (±0.1%), 4.1%
(±0.1%) and 4.4% (±0.2%) at MOIs of 10, 20 and 50, re-
spectively, at 5 days post transduction (Supplementary Fig-
ure S1). Indels were not detected in A549 cells (wild-type
EGFR allele); frequencies were below 0.5% at anMOI of 50
(Figure 2B).
To investigate whether targeted cleavage and disruption
of the EGFR mutant allele could induce death of can-
cer cells, we conducted an MTT cell proliferation assay
(Figure 2D and Supplementary Figure S2). Co-treatment
with Ad/sgEGFR and Ad/Cas9 led significant cancer cell
killing of H1975 cells in a dose-dependent manner, indicat-
ing that disruption of the EGFR mutant allele was essen-
tial for cancer cell killing effect. In contrast, co-treatment
with Ad/sgEGFR and Ad/Cas9 did not significantly af-
fect the viability of A549 cells carrying the wild-type EGFR
allele. Collectively, these results suggest that mutant allele-
specific Cas9 can efficiently distinguish the EGFR mutant
allele from thewild-type allele, leading to targeted oncogene
disruption and cancer cell death.
Targeted mutant allele disruption in a murine xenograft
model of human lung adenocarcinoma
To investigate oncogenic mutant allele-specific cleavage
mediated by CRISPR/Cas9, we used xenograft mice im-
planted with either H1975 or A549 cancer cells. When sub-
cutaneously implanted tumors reached a volume of 80–100
mm3, we intratumorally injected a mixture of Ad/sgEGFR
andAd/Cas9 at a dose of 5× 1010 VPs every other day for a
total of three times. As negative controls, we injected either
a mixture of Ad/Cas9 with Ad/empty vector or PBS alone.
Co-treatment with Ad/sgEGFR and Ad/Cas9 resulted in
indels at frequencies of 50% (±5.3%), 40% (±2.8%) and
35% (±4.1%) at the EGFR mutant allele in H1975-derived
tumors at day 7, 9 and 11, respectively, after the first injec-
tion (Figure 3A). Interestingly, indels were not detectable in
the H1975 tumor xenograft 31 days post-injection, suggest-
ing that disruption of the mutant EGFR allele contributes
to cancer cell killing. Of note, indels at the wild-type EGFR
allele were minimally detected in H1975 tumors, with a fre-
quency of 2.6% (±0.4%), 2.3% (±0.2%) and 0.9% (±0.1%)
at day 7, 9 and 11 post-injection, respectively (Figure 3A).
No indels were detectably induced at the wild-type EGFR
mutant allele in A549-derived tumors (Figure 3B). These
results suggest that Ad-mediated EGFR oncogene-specific
Cas9 expression can disrupt the EGFR mutant allele in
H1975 cells with high accuracy in vivo.
We next investigated whether the mutant allele-specific
nuclease had off-target effects. Off-target nuclease activities
were measured by targeted deep sequencing at 17 potential
off-target sites, identified using CAS-OFFinder algorithm
(http://www.rgenome.net/cas-offinder/) that differed from
the on-target site by up to 3 nt in the human genome. No
indels were detectably induced at these sites in Ad/sgEGFR
and Ad/Cas9 co-treated H1975 tumors 7 days after the first
injection (Figure 3C and Supplementary Table S1).
Rapid tumor regression and prolonged survival rate due to
EGFR mutant allele disruption
We then assessed the therapeutic efficacy of Ad-
CRISPR/Cas9 in tumor xenograft mice implanted with
H1975 or A549 cells to investigate whether targeted dis-
ruption of the oncogenic mutant allele using Cas9 could be
translated to tumor regression (Figure 4A). Co-treatment
with Ad/sgEGFR and Ad/Cas9 led to significant tumor
growth inhibition, resulting in an average tumor size of
324.1 (± 83.4) mm3 (P< 0.001). Tumor volumes in control
groups treated with either PBS or Ad/Cas9 with Ad/empty
vector increased over time and reached an average size of
1755.5 (±111.3) mm3 or 1496.5 (±177.3) mm3, respectively,
31 days after the treatment (Figure 4A). Thus, the EGFR
mutation-specific Cas9 reduced tumor size by 81.5% and
78.3%, compared to the PBS and Ad/Cas9 treated controls,
respectively.
The survival rate was also significantly increased in ani-
mals co-treated with Ad/sgEGFR and Ad/Cas9 compared
to control groups treatedwith eitherAd/Cas9 or PBS alone.
By day 31 following treatment in H1975 tumor-bearing
mice, all animals in the Ad/sgEGFR and Ad/Cas9 co-
treated group were still viable, whereas all animals in con-
trol groups treated with either Ad/Cas9 or PBS were dead
(P < 0.001). As expected, there was no significant differ-
ence in tumor size between CRISPR/Cas9 and PBS treated
mice implanted with A549 cells harboring the wild-type
EGFR allele (Figure 4B). Only 0% or 14.3% of the animals
were viable in the Ad/sgEGFR and Ad/Cas9 co-treated
or PBS control groups, respectively (P < 0.001). Through-
out the course of the study, no signs of systemic toxicity,
such as diarrhea, loss of weight or cachexia, were observed.
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Figure 2. Specific excision of the oncogenic EGFR allele induces cytopathic effect. (A) Representative diagram of E1-deleted adenovirus type 5 encoding
either SpCas9 or sgRNA targeting the EGFR gene. (B) Mutation frequencies at the EGFR target site in H1975 and A549 cells were examined via targeted
deep sequencing day 1, 2 and 5 after co-transduction of Ad/sgEGFR and Ad/Cas9 withMOIs of 10, 20 and 50. (C) EGFRmRNA levels, normalized with
an 18S rRNA internal control, were determined day 2 after co-infection of H1975 cells with Ad/sgEGFR and Ad/Cas9. (D) CRISPR/Cas9-mediated
cell killing efficacy in H1975 or A549 cells. Cells were treated with Ad/sgEGFR, Ad/Cas9, or Ad/sgEGFR + Ad/Cas9; day 2 post-treatment, an MTT
assay was performed. Bars represent the mean ± S.E.M (n = 3). * (P < 0.05), ** (P < 0.01), *** (P < 0.001), ns: not significant.
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Figure 3. Selective oncogene disruption using Ad/sgEGFR and Ad/Cas9 in vivo. Indels at the wild-type (gray bar) and mutant EGFR alleles (blue bar) in
(A) H1975 or (B) A549 tumor xenografts co-injected with Ad/sgEGFR and Ad/Cas9 at day 7, 9, 11 and 31 after the first injection. Tumor-bearing mice
were given intratumoral injections of PBS (mock) or 5 × 1010 Ad VPs (Ad/Cas9 + Ad/empty vector or Ad/sgEGFR + Ad/Cas9) on days 1, 3 and 5.
Values represent the mean ± S.E.M. (n= 3 to 4). **P < 0.01. ns: not significant. (C) No off-target indels were detectably induced at eight homologous
sites that differed from the on-target sites by up to 3 nt in the human genome. Mismatched nucleotides are shown in blue and PAM sequences in red, On;
on-target site, OT; off-target site. Red arrow indicates cleavage position within the 19-bp target sequences. Error bar indicates S.E.M. (n = 3 to 4).
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Figure 4. Antitumor effect and survival benefit of adenoviral delivery of CRISPR/Cas9 to tumor xenograft models. (A) H1975 tumor-bearing mice were
given intratumoral injections of PBS or 5 × 1010 VPs (Ad/Cas9 + Ad/empty vector or Ad/sgEGFR and Ad/Cas9) on days 1, 3 and 5. Tumor growth was
monitored every other day until 31 days post injection. Values represent the mean ± S.E.M. for eight animals per group. ***P < 0.001 compared with the
PBS and Ad/Cas9 treated groups. The percentage of surviving mice was determined by monitoring tumor growth-related events (tumor size < 800 mm3)
over a time period. (B) A549 tumor-bearing mice were given intratumoral injections of PBS or 5 × 1010 Ad VPs (Ad/sgEGFR and Ad/Cas9) on days 1,
3 and 5. Tumor growth was monitored every other day until the end of the study. Bar represent the mean ± S.E.M. for eight animals per group. NS; not
significant compared with the PBS treated groups. The percentage of surviving mice was determined by monitoring tumor growth-related events (tumor
size < 800 mm3) over a time period. (C) PBS, Ad/Cas9 + Ad/empty vector or Ad/sgEGFR and Ad/Cas9 was injected on days 1, 3 and 5 into established
H1975 tumors in nude mice. Tumors were harvested on day 7 for histological analysis. H & E staining and immunohistochemical staining of PCNA and
EGFR were performed on tumor sections from each group of mice.
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Taken together, these results suggest that highly efficient
and mutant allele-specific CRISPR/Cas9-mediated precise
excision contributes to significant tumor regression, leading
to prolonged survival in vivo.
Antitumor efficacy of oncogenic mutant-specific Cas9
The antitumor efficacy of oncogenic mutant-specific
CRISPR/Cas9 was further investigated by histological and
immunohistochemical analysis (Figure 4C). H & E staining
revealed a markedly reduced number of viable tumor cells
and more extensive necrotic regions in Ad/sgEGFR and
Ad/Cas9 co-treated tumors than the Ad/Cas9 or PBS
treated control groups. There was no noticeable immune
cell infiltration in all tested tumor tissues. Moreover,
Ad/sgEGFR and Ad/Cas9 co-treated tumor tissues ex-
hibited markedly lower levels of PCNA compared with
Ad/Cas9 or PBS treated tissues (P < 0.001). Importantly,
tumor tissues from mice co-treated with Ad/sgEGFR and
Ad/Cas9 showed a 1284- or 958-fold reduction in EGFR
protein expression compared with those treated with either
PBS or Ad/Cas9, respectively, implying that Ad-mediated
CRISPR/Cas9 can efficiently target and attenuate EGFR
mutant protein expression, leading to decreased tumor cell
proliferation and enhanced cell death in H1975 tumors (P
< 0.001). Taken together, these data indicate that the Ad-
mediated CRISPR/Cas9 system provides strong inhibitory
effects on tumor growth, resulting in an increased survival
rate in EGFR-mutated tumor-bearing mice.
DISCUSSION
CRISPR/Cas9-mediated genome editing is a powerful new
technique that can generate targeted genetic modifica-
tions in eukaryotic cells and organisms. This system has
been utilized to correct disease-associated genetic defects
and to inactivate disease-causing wild-type genes (47–50).
Several studies that aim to remove oncogenes using the
CRISPR/Cas9 system are underway and may have thera-
peutic potential (23–31). Huang et al. demonstrated that
CRISPR/Cas9 system targeting EGFR exon 17 can in-
hibit NF-B activation in EGFRwt/vIII glioma cells (25).
However, these approaches still provide limited specificity,
with indiscriminate disruption of both the wild-type proto-
oncogene and mutant oncogene alleles, emphasizing the ur-
gent need for more precise targeted therapy.
In this study, we demonstrated a novel approach, a mu-
tated oncogene surgery, to destroy the predominant onco-
genic EGFRmutation in lung cancer using CRISPR/Cas9.
Delivery of EGFRmutation-specific CRISPR/Cas9 via Ad
into EGFR mutant-bearing tumors resulted in precise ex-
cision at the oncogenic mutation site, demonstrating tar-
get specificity of the approach. We showed mutant allele-
specific gene disruption in H1975 tumors in vivo. Disrup-
tion of the carcinogenic EGFRmutation (L858R) in H1975
tumors resulted in potent inhibition of cancer cell prolifer-
ation, followed by rapid tumor regression. Yet, we cannot
rule out the possibility of disruption of neighboring cells
which lack the PAM generating mutant allele. However,
indels and its cytotoxicity associated with CRISPR/Cas9
were not detectably induced in A549 cells which harbor
wild-type EGFR alleles only. These results are in line with
in vivo data that tumor growth inhibition was not shown
in Ad/sgEGFR and Ad/Cas9 co-treated A549 tumors,
demonstrating the specificity of the system. This approach
could also be extended to disrupt other cancer-driving mu-
tations that generate PAM sequences recognized by SpCas9
(Supplementary Table S2) for multiple gene editing in can-
cers characterized by frequent mutation heterogeneity. In
this study, we showed the specificity of CRISPR/Cas9 for
targeting a mutant allele that generates a 5′-NGG-3′ PAM
sequence. Cas9 variants with altered PAM recognition can
be employed to target other oncogenic mutations. Cong
et al. has previously reported that single-base mismatches
in the PAM-proximal seed region abolished genomic cleav-
age by SpCas9 (17), suggesting that mutations in the seed
sequence could also be targetable.
Mutated EGFR targeting CRISPR/Cas9 system induced
indels with a frequency of 60–80% at the target site (L858R)
in H1975 cells (Figure 2B), followed by 60% decrease in
EGFR mRNA expression level (Figure 2C). We found that
H1975 cells harbor 25% wild-type alleles and 75% mutant
alleles of the total allele composition (Supplementary Table
S5). Based on this, we speculate that indels at frequencies of
80% in mutant alleles led to 60% decrease in total EGFR
expression. Furthermore, there was a negative correlation
between indels and viability of H1975 cells in vitro (Figure
2B and D), suggesting that disruption of the mutant EGFR
alleles leads to cell death. These results are in line with other
reports demonstrating that L858R activating mutation pro-
motes malignant pleural tumor formation and polypoid
(51). Thus, the inhibition of mutated EGFR (L858R) using
gefitinib leads to the death of NSCLC (52,53).
Taken together, CRISPR/Cas9-mediated death of mu-
tated EGFR-expressing cancer cells and subsequent change
in genetic composition of cancer cell population can atten-
uate malignancy of cancer. Similar results were obtained in
vivo in which a positive correlation between indels in the
mutated EGFR gene and tumor growth inhibition was ob-
served (Figures 3 and 4). Specifically, downregulation of
EGFR protein levels by CRISPR/Cas9-mediated disrup-
tion of L858R mutation resulted in attenuated tumor bur-
den and improved survival of tumor-bearing mice. Tumors
treated with mutated EGFR gene targeting CRISPR/Cas9
showed extensive necrosis and decreased proliferation (Fig-
ure 4C), indicating that decreased mutant allele composi-
tion in a H1975 tumor can efficiently inhibit tumor cell pro-
liferation and EGFR signaling pathway. Consistent with
these results, others have reported that ablation of onco-
genicmutations using theCRISPR/Cas9 system can signifi-
cantly improve the survival rate of tumor-bearing mice (31).
Taken together, it indicates that the CRISPR/Cas9 system
can be a promising method of cancer treatment to ablate or
correct cancer driving mutations.
Of interest, the in vivo data of Figure 3 shows a
time-dependent reduction in indel rate with the promo-
tion of tumor regrowth observed in tumors treated with
CRISPR/Cas9 from day 21 and onward (Figure 4A).
Specifically, tumor growth between day 1 and 21 averaged
1.89 mm3/day, whereas average tumor growth from day 21
to 31 was 22.1 mm3/day. One possible explanation for tu-
mor regrowth is that a time-dependent decrease in indel fre-
7906 Nucleic Acids Research, 2017, Vol. 45, No. 13
quency in CRISPR/Cas9-treated tumors may lead to re-
proliferation of unedited mutant EGFR expressing cancer
cells, ultimately leading to tumor regrowth. Based on these
results, administrating second cycle of treatment at later
time period might induce tumor regrowth inhibition.
The CRISPR/Cas9 system can be delivered efficiently to
target tumors via the adenoviral vector system (47,54,55).
In this work, we utilized a replication-incompetent Ad as
a carrier to deliver CRISPR/Cas9 to lung cancer with high
accuracy. Ad has several advantages for applications in can-
cer gene therapy: the ability to infect both dividing and non-
dividing cells, a high level of gene expression, the production
of high-titer stocks and no risk of insertional mutagenesis
(56–58). We demonstrate improved knock-out efficiency of
CRISPR/Cas9 at the oncogenic EGFR mutation by using
Ad as a vehicle compared with plasmid-based delivery. The
efficacy of this approach could be further enhanced by uti-
lizing oncolytic Ad, a cancer-specific replicating Ad (59,60),
to induce preferential and highly specific expression of Ad
moieties at a high level in tumor cells. Furthermore, we have
utilized immune-deficient animal model to establish human
xenograft tumor model, thus immune response-mediated
killing of cancer cells was excluded in this study. However,
oncolytic Ad, Cas9 or sgRNA may induce an anti-tumor
immune response (40,61–64), ultimately instigating antitu-
mor immune response and inhibiting tumor growth.We be-
lieve that our system in immune-competent animal model
may elicit more potent antitumor efficacy and evaluation
of immune response mediated by this system should be ex-
plored in future studies. No off-target effect was detectably
induced inAd/sgEGFRandAd/Cas9 co-treatedH1975 tu-
mors. However, the potential off-target effect of this system
should be further investigated for a long period of time. The
use of tissue- or tumor-specific promoters to regulate Cas9
protein expression may improve target specificity for selec-
tive disruption of cancer-driving mutant alleles.
Taken together, our results demonstrate that expression
ofmutant allele-specific CRISPR/Cas9 in conjunction with
Ad-mediated delivery can be a powerful technique for pre-
cise disruption of oncogenic mutations and inhibition of tu-
mor growth. Our results indicate that the use of the mu-
tant allele-specific CRISPR/Cas9 could overcome the cur-
rent limitations of conventional cancer therapies with their
side effects caused by unselective cell killing. Application of
this platform offers promise for targeted cancer therapy and
treating other mutation-associated diseases.
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